

## New Agreement for ZOMETA<sup>®</sup>

Oncology Associates is pleased to announce ZOMETA<sup>®</sup> (zoledronic acid) has been added to the Novartis agreement, effective **October 1, 2004**. The agreement will run until December 31, 2004.

ZOMETA<sup>®</sup> is offered to all OA members in good standing at a significant **discount of 5%**. The product is available in 4 mg/5ml vials.

ZOMETA<sup>®</sup> Injection is indicated for the treatment of hypercalcemia of malignancy. ZOMETA<sup>®</sup> is also indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

Contact Oncology Associates at **888-732-7352** with any questions about the Novartis agreement. For more information about ZOMETA<sup>®</sup>, visit **[www.zometa.com](http://www.zometa.com)**.

<b>Product Name</b>	<b>Strength</b>	<b>NDC#</b>	<b>Vials/pkg</b>	<b>% Discount</b>
Zometa <sup>®</sup>	4 mg/5ml vial	0078-0387-25	1	5%